BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

...and older.Long-acting growth hormone therapy from Pfizer, Opko meets in Phase IIIPfizer Inc. (NYSE:PFE) and Opko Health Inc....
...III trial to treat children ages 3-17 with growth hormone deficiency. Under a 2014 deal, Opko...
...whether the technology could be applied to vaccines for COVID-19 and other infectious diseases. BC Staff Kronos Bio Pfizer Opko Sensei...
BioCentury | Mar 29, 2019
Clinical News

Opko's diabetes therapy meets in Phase IIb

...adult Type II diabetics who had inadequate glucose control with metformin and/or diet and exercise. Opko Health Inc....
...will be presented the American Diabetes Association meeting in San Francisco in June. Sandi Wong, Staff Writer OPK88003 Opko Health Inc. Glucagon...
BioCentury | Feb 28, 2019
Distillery Therapeutics

Infectious disease

...models of influenza infection. TARGET/MARKER/PATHWAY: Influenza A virus hemagglutinin (HA) LICENSING STATUS: Patented; licensed to Opko Health Inc....
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...million, respectively, while The Medicines Co. and Omeros Corp. each opted for convertible note deals. Opko Health Inc....
...Idorsia Ltd., Allschwil, Switzerland Loxo Oncology Inc. (NASDAQ:LOXO), Stamford, Conn. Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Opko Health Inc....
BioCentury | Nov 16, 2018
Financial News

Opko raises $92.5M in private placement

...the sale of 26.5 million shares at $3.49. The price is a 10% discount to Opko's...
...$3.49 on Nov. 8, the day before the placement was publicly announced. An affiliate of Opko...
...agreement were announced in a Nov. 9 SEC filing. Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK), Miami, Fla. Allison Johnson Opko Health Inc....
BioCentury | Sep 10, 2018
Company News

Management tracks: PolarityTE, Medivir

...Securities and Exchanges Commission filed charges against him alleging his involvement in "pump-and-dump" schemes (see "Opko's...
BioCentury | Sep 7, 2018
Financial News

Opko's Frost among those charged in ‘pump-and-dump’ schemes

...participated in “pump-and-dump” schemes involving penny stock companies. Frost, who is chairman and CEO at Opko Health Inc....
...was named in the indictment along with nine other individuals and several companies, including Opko. Opko...
...prices. According to the filing, one article, published under the pseudonym Wall Street Advisors, identified Opko...
BioCentury | Jul 6, 2018
Financial News

Biotech stocks rise after positive AD data

...following the news, including AC Immune S.A. (NASDAQ:ACIU), which added $3.56 (38%) to $12.86, and Opko Health Inc....
BioCentury | Jan 19, 2018
Clinical News

Tesaro informs doctors of hypersensitivity risks with Varubi

...worldwide rights to the neurokinin 1 receptor (NK1R; TACR1) antagonist from Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK). Opko Health Inc....
...NASDAQ:TSRO), Waltham, Mass. Product: Varubi rolapitant IV (SCH 619734) Business: Gastrointestinal Chris Lieu IV Varubi rolapitant IV SCH 619734 Varubi IV Opko Health Inc. Tesaro...
BioCentury | Jan 9, 2018
Finance

Stars in China

...treat biallelic retinal pigment epithelium-specific protein 65kDa (RPE65) mutation-associated retinal dystrophy Tesaro Inc. (NASDAQ:TSRO) / Opko Health Inc....
Items per page:
1 - 10 of 229
BioCentury | Oct 9, 2020
Deals

Oct. 8 Quick Takes: Kronos ready for NASDAQ debut; plus Sensei, TCRyption, Jazz, Pfizer-Opko and Moderna

...and older.Long-acting growth hormone therapy from Pfizer, Opko meets in Phase IIIPfizer Inc. (NYSE:PFE) and Opko Health Inc....
...III trial to treat children ages 3-17 with growth hormone deficiency. Under a 2014 deal, Opko...
...whether the technology could be applied to vaccines for COVID-19 and other infectious diseases. BC Staff Kronos Bio Pfizer Opko Sensei...
BioCentury | Mar 29, 2019
Clinical News

Opko's diabetes therapy meets in Phase IIb

...adult Type II diabetics who had inadequate glucose control with metformin and/or diet and exercise. Opko Health Inc....
...will be presented the American Diabetes Association meeting in San Francisco in June. Sandi Wong, Staff Writer OPK88003 Opko Health Inc. Glucagon...
BioCentury | Feb 28, 2019
Distillery Therapeutics

Infectious disease

...models of influenza infection. TARGET/MARKER/PATHWAY: Influenza A virus hemagglutinin (HA) LICENSING STATUS: Patented; licensed to Opko Health Inc....
BioCentury | Jan 12, 2019
Finance

Warning: cash needed

...million, respectively, while The Medicines Co. and Omeros Corp. each opted for convertible note deals. Opko Health Inc....
...Idorsia Ltd., Allschwil, Switzerland Loxo Oncology Inc. (NASDAQ:LOXO), Stamford, Conn. Omeros Corp. (NASDAQ:OMER), Seattle, Wash. Opko Health Inc....
BioCentury | Nov 16, 2018
Financial News

Opko raises $92.5M in private placement

...the sale of 26.5 million shares at $3.49. The price is a 10% discount to Opko's...
...$3.49 on Nov. 8, the day before the placement was publicly announced. An affiliate of Opko...
...agreement were announced in a Nov. 9 SEC filing. Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK), Miami, Fla. Allison Johnson Opko Health Inc....
BioCentury | Sep 10, 2018
Company News

Management tracks: PolarityTE, Medivir

...Securities and Exchanges Commission filed charges against him alleging his involvement in "pump-and-dump" schemes (see "Opko's...
BioCentury | Sep 7, 2018
Financial News

Opko's Frost among those charged in ‘pump-and-dump’ schemes

...participated in “pump-and-dump” schemes involving penny stock companies. Frost, who is chairman and CEO at Opko Health Inc....
...was named in the indictment along with nine other individuals and several companies, including Opko. Opko...
...prices. According to the filing, one article, published under the pseudonym Wall Street Advisors, identified Opko...
BioCentury | Jul 6, 2018
Financial News

Biotech stocks rise after positive AD data

...following the news, including AC Immune S.A. (NASDAQ:ACIU), which added $3.56 (38%) to $12.86, and Opko Health Inc....
BioCentury | Jan 19, 2018
Clinical News

Tesaro informs doctors of hypersensitivity risks with Varubi

...worldwide rights to the neurokinin 1 receptor (NK1R; TACR1) antagonist from Opko Health Inc. (NASDAQ:OPK; Tel Aviv:OPK). Opko Health Inc....
...NASDAQ:TSRO), Waltham, Mass. Product: Varubi rolapitant IV (SCH 619734) Business: Gastrointestinal Chris Lieu IV Varubi rolapitant IV SCH 619734 Varubi IV Opko Health Inc. Tesaro...
BioCentury | Jan 9, 2018
Finance

Stars in China

...treat biallelic retinal pigment epithelium-specific protein 65kDa (RPE65) mutation-associated retinal dystrophy Tesaro Inc. (NASDAQ:TSRO) / Opko Health Inc....
Items per page:
1 - 10 of 229